Sudeep Pharma delivered a strong listing on Friday, debuting at more than a 23% premium to its IPO price. The company’s ₹895-crore public issue had seen stellar demand, recording a 93.71 times subscription between November 21 and 25. On the NSE, Sudeep Pharma shares opened at ₹730, reflecting a 23.10% premium over the upper price band of ₹593. On the BSE, the stock began trading at ₹725, a 22.26% premium, taking the company’s post-listing market capitalisation to ₹8,188.78 crore.
The debut surpassed grey-market predictions, which had indicated about a 20% premium. Earlier, the company had raised ₹268.5 crore from anchor investors. Of the total proceeds, ₹75.81 crore from the fresh issue will be allocated for capital expenditure, including new machinery for its production facility at Nandesari (Facility 1) in Gujarat, with the remainder earmarked for general corporate purposes.
Sudeep Pharma operates as a technology-driven producer of excipients and specialty ingredients used across pharmaceutical, food and nutrition segments, supporting the broader global healthcare landscape.
+ There are no comments
Add yours